LinXis receives TKI-PPP grant

The project is a collaboration between LinXis and the Department of Pulmonary Medicine of the Amsterdam University Medical Center (AUMC). Read about the project on the site of the Dutch Lung Foundation.

Key to the project is synergy. While LinXis holds extensive expertise in targeted drug delivery using its proprietary Fibrobody as a validated targeting vector, the department of Pulmonary Medicine is a leading center of expertise for the preclinical and clinical study of pulmonary fibrosis.

The project perfectly fits into our company strategy. Parallel to the preclinical FibroTarget project, we will proceed with the validation of our Fibrobody in patients suffering fibrotic disease, including patients suffering pulmonary fibrosis, in a clinical imaging study. While the FibroTarget project will provide us with optimized Fibrobody-Drug conjugates, the clinical imaging study in parallel will identify those patients that will most benefit from treatment. This combined approach is fully in line with our central philosophy of de-risking drug development at the earliest stage, using imaging-based technologies.

"Pulmonary Fibrosis is a huge and essentially unmet medical need. Currently, two drugs have been approved for the treatment of pulmonary fibrosis, but they are only partially effective. What is worse, is that they exert side effects so severe that many patients decide to discontinue their use. Our collective goal is to deliver medication selectively to the lungs of people with pulmonary fibrosis, more specifically to the activated myofibroblasts which are the disease-driving cells within these lungs, increasing effectiveness and reducing side effects at the same time." - 

Bart Nijmeijer, CEO of LinXis Biopharmaceuticals, and Jan Willem Duitman, Assistant Professor at the Department of Pulmonary Medicine of Amsterdam University Medical Center.